Overview and Scope

Inactivated vaccines, also known as killed vaccines, are a type of vaccine that contains viruses or bacteria that have been killed or inactivated using heat, chemicals, or radiation. These vaccines are designed to stimulate an immune response without causing disease in the vaccinated individual.

Sizing and Forecast

The inactivated vaccines market size has grown steadily in recent years. It will grow from $5.95 billion in 2023 to $6.19 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%.  The  growth in the historic period can be attributed to polio eradication efforts, influenza vaccination programs, emerging infectious diseases, regulatory approvals.

The inactivated vaccines market size is expected to see steady growth in the next few years. It will grow to $7.33 billion in 2028 at a compound annual growth rate (CAGR) of 4.3%.  The growth in the forecast period can be attributed to pandemic preparedness, expanding vaccine coverage, biomanufacturing advancements, health equity initiatives. Major trends in the forecast period include mrna vaccine platforms, combination vaccines, thermostable vaccines, digital vaccine passports.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Segmentation & Regional Insights

The inactivated vaccines market covered in this report is segmented –

1) By Type: Viral Vaccine; Bacterial Vaccine

2) By Method Of Inactivation: Solvent Detergent; Radiation; pH Concentration; Heat Inactivation; Other Methods Of Inactivation

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels

Top Major Players:
Pfizer Inc.
Johnson & Johnson Services Inc.
Sinopharm Group Co. Ltd.
Merck & Co. Inc.
Sanofi S.A

North America was the largest region in the inactivated vaccines market in 2023.

North America was the largest region in the inactivated vaccines market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

 Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

Major Driver Impacting Market Growth

 The increasing prevalence of infectious diseases is expected to propel the growth of the inactivated vaccine market going forward. Infectious diseases are illnesses caused by pathogens such as bacteria, viruses, fungi, or parasites that can spread from person to person, resulting in a wide range of symptoms and health complications. Tuberculosis is one type of infectious disease. Inactivated vaccines use non-living pathogens to stimulate an immune response, effectively preventing diseases like polio, hepatitis A and influenza. For instance, in October 2022, according to the Global Tuberculosis Report published by the World Health Organization, a Switzerland-based global health agency, there will be a 4.5% increase in the global incidence of tuberculosis from the projected 10.1 million cases to 10.6 million cases in 2021. The majority of tuberculosis cases were reported in the Southeast Asia region, accounting for 45% of the total, followed by Africa with 23% of the cases. Therefore, the increasing prevalence of infectious diseases is driving the growth of the inactivated vaccine market.

Key Industry Players

 Major players in the inactivated vaccines market are  Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

The inactivated vaccines market report table of contents includes:

1. Executive Summary
2. Inactivated Vaccines Market Characteristics
3. Inactivated Vaccines Market Trends And Strategies
4. Inactivated Vaccines Market - Macro Economic Scenario
5. Global Inactivated Vaccines Market Size and Growth
….
32. Global Inactivated Vaccines Market Competitive Benchmarking
33. Global Inactivated Vaccines Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Inactivated Vaccines Market
35.Inactivated Vaccines Market Future Outlook and Potential Analysis
36. Appendix

Explore the trending research reports from TBRC:

 Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On: 
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model